Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders

作     者：Deng-Ho Yang Ling-Jun Ho Jenn-Haung Lai 

作者机构：Division of RheumatologyImmunology and AllergyDepartment of Internal MedicineTaichung Armed-Forces General Hospital Institute of MedicineChung Shan Medical University Institute of Cellular and System MedicineNational Health Research Institute Graduate Institute of Medical ScienceNational Defense Medical Center Division of AllergyImmunology and RheumatologyDepartment of Internal MedicineChang Gung Memorial HospitalChang Gung University 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2014年第20卷第11期

页      面：2962-2970页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：Supported by(In part)the National Science Council,NSC 101-2314-B-182A-103-MY3 Chang Gung Memorial Hospi-tal,CMRPG3B1751E 

主　　题：Hepatitis C virus Autoantibody Autoimmune Biomarker Cytokine 

摘      要：During the course of chronic hepatitis C virus(HCV)infection,various extrahepatic manifestations of autoimmune disorders may occur,including arthralgia/arthritis,sicca complex,purpura,cutaneous ulcer,and thyroid *** addition,the prevalence of circulating autoantibodies is high among patients with HCV *** detected autoantibodies in HCVinfected patients include rheumatoid factor,antinuclear antibody,anti-SSA/anti-SSB antibody,cryoglobulin,antineutrophil cytoplasmic antibody,anti-smooth muscle antibody,anti-liver and anti-thyroid *** autoantibodies may be associated with underlying autoimmune disorders or liver inflammation in HCV infection.A possible reason for antibody production is overactivation and proliferation of B lymphocytes,via the interaction with the surface protein of *** immunotherapy can cause HCV flare-up or liver damage,overdiagnosis of HCV-related autoimmune symptoms as primary autoimmune disorders should be *** review describes biomarkers that are useful in clinically evaluating autoimmune manifestations and disorders associated with HCV infection.